Design considerations for early-phase clinical trials of immune-oncology agents
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Design considerations for early-phase clinical trials of immune-oncology agents ; volume:6 ; number:1 ; day:22 ; month:8 ; year:2018 ; pages:1-10 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (22.8.2018), 1-10, 12.2018
- Urheber
-
Wages, Nolan A.
- Beteiligte Personen und Organisationen
-
Chiuzan, Cody
Panageas, Katherine S.
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0389-8
- URN
-
urn:nbn:de:101:1-2018101620553299790461
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wages, Nolan A.
- Chiuzan, Cody
- Panageas, Katherine S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical trials in oncology
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
Phase I Clinical Trials in Oncology
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
Immune oncology, immune responsiveness and the theory of everything
Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
Immune modulation by infectious agents
Umbrella and basket trials in oncology: ethical challenges
Clinical trials in oncology
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
Phase I Clinical Trials in Oncology
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
Immune oncology, immune responsiveness and the theory of everything
Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
Immune modulation by infectious agents
Umbrella and basket trials in oncology: ethical challenges
Clinical trials in oncology
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
Phase I Clinical Trials in Oncology
Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials
Immune oncology, immune responsiveness and the theory of everything
Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
Immune modulation by infectious agents